DNDi joins forces with leading organizations to tackle the deadly tropical disease, Visceral Leishmaniasis

The Consortium for the Control and Elimination of Visceral Leishmaniasis, known as KalaCORE, is a new partnership between the Drugs for Neglected Diseases initiative, the London School of Hygiene and Tropical Medicine, Médecins Sans Frontières and Mott MacDonald. The consortium has been appointed by the Department for International Development (DFID) to tackle Visceral Leishmaniasis (VL) in South Asia and East Africa.

Strengthening the Malaria Treatment Arsenal for Children in Africa

Dr Bernhards OgutuDr Sodiomon SirimaDr Bernhards Ogutu, KEMRI, Kenya and Dr Sodiomon Sirima, CNRFP, Burkina Faso
[November 2014]

Today, we have results of a large clinical trial conducted in three countries across both East and West Africa by DNDi in partnership with the Central National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, the Kenya Medical Research Centre (KEMRI) in Kenya, the National Institute for Medical Research (NIMR), and the Ifakara Health Institute in Tanzania. ASMQ (artesunate-mefloquine) fixed dose combination (FDC) has proven safe and efficacious in treating children with uncomplicated P. falciparum malaria in Africa, and is non-inferior to artemether-lumefantrine (AL).

Learning to deliver: Challenges in NTD drug research and development

Graeme BilbeDr Graeme Bilbe, Research & Development Director, DNDi
[September 2014]

DNDi and other not-for-profit drug research and development (R&D) organizations have explored new R&D pathways to develop and deliver safe, adapted, and affordable treatments for neglected diseases. Most of these new pathways have shown signs of success, while several have faced challenges that span across the drug discovery and development processes.

R&D status September 2014: DNDi Leishmaniasis programme

[September 2014]

Leishmaniasis is transmitted by the bite of a sand fly. It is a complex disease with over a million new cases occurring every year and 350 million people living at risk worldwide in 98 countries. The disease presents several different forms, the most common of which are visceral leishmaniasis (VL), which is fatal without treatment, and cutaneous leishmaniasis (CL).

R&D status September 2014: DNDi Filarial diseases programme

[September 2014]

Filarial diseases include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis. They are caused by parasitic worms which are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.

R&D status September 2014: DNDi Sleeping Sickness programme

[September 2014]

Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the tsetse fly. While currently its prevalence is declining, HAT is still a threat to millions of people across Sub-Saharan Africa with 83% (2013) of all cases in the Democratic Republic of Congo (DRC).

R&D status September 2014: DNDi Malaria programme

[September 2014]

Malaria is transmitted by mosquitoes. It kills one child every 30 seconds in sub-Saharan Africa and is the leading parasitic cause of morbidity and mortality worldwide. 3.2 billion people are at risk. DNDi with its partners have delivered two fixed-dose combination (FDC) of the five artemisinin-based drugs (ACTs), FDC’s that were recommended by WHO for the treatment of uncomplicated falciparum malaria.

Conducting clinical trials for sleeping sickness in remote areas of the Democratic Republic of the Congo – Overcoming Operational Challenges and Reaping Health System Benefits

Wilfried MutomboDr. Wilfried Mutombo, Coordinating investigator, Fexinidazole study for HAT
[July 2014]

At the time DNDi and its partners are extending the clinical trial on fexinidazole, the first new oral treatment tested for sleeping sickness, to the early stages of the disease in adults and to children between 6 and 14 years of age, it is important to remember how clinical trials in remote areas of a country such as the Democratic Republic of the Congo (DRC) can be a daunting challenge, but can also bring lasting benefits to local communities and researchers, and to the health system overall.

Filaria in Ghana – Slideshow

Filaria is a group of neglected tropical diseases infecting over 150 million people in sub-Saharan Africa, Asia, and Latin America. The two main filarial diseases, onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis), devastate the lives of patients, causing debilitating symptoms and social discrimination. In March 2014, DNDi traveled to rural Ghana to meet and interview patients with filaria and the physician-researchers treating them.

DNDi Mourns the Loss of Dr. Richard Rockefeller

New York – June 14, 2014 – The Drugs for Neglected Diseases initiative (DNDi) wishes to extend its deepest condolences to the Rockefeller Family for the tragic loss of Dr. Richard Rockefeller, who was killed in a plane crash the morning of June 13.

Modern drug discovery and the fight against NTDs: How can the PDP model enhance and accelerate the R&D process?

Robert Don Charles MowbrayRobert Don, Discovery & Preclinical Director, and Charles Mowbray, Head of Drug Discovery, DNDi
[May 2014]

Important advances have been made in recent years to optimize the use of existing medicines to treat neglected tropical diseases (NTDs) but, while providing urgently needed improvements on previous treatments, they are often still not ideal. There remains an urgent need to design and develop modern drugs to treat these diseases.

Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D

A new paper recently commissioned by DNDi to examine the possibilities of creating a pooled international R&D fund for the Demonstration Projects that were selected as part of the process following on the report of the WHO Consultative Expert Working Group on Research and Development (CEWG): “Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D.”

DNDi and South African Department of Health Sign a Partnership Agreement on Improving Access to Paediatric HIV Treatment In South Africa

On 7 April 2014, the Director-General: Health, Ms P Matsoso and the Executive Director: DNDi, Dr Bernard Pécoul, signed a Partnership Agreement on Improving Access to Paediatric HIV Treatment in South Africa. DNDi’s paediatric HIV project, in partnership with Cipla Ltd., and with the support of  the UNITAID, in addition to the French Development Agency (AFD), Médecins Sans Frontières/Doctors Without Borders (MSF), and the UBS Optimus Foundation, is to develop two 4-in-1 lopinavir-based fixed dose combinations as well as a solid formulation of ritonavir booster that are suitable for young children infected with HIV, as well as with tuberculosis and HIV. These formulations, ultimately, will be in solid ‘granular’ form that is palatable and requires no refrigeration, alleviating much of the current treatment burden on the children, their mothers and caregivers, and healthcare workers.

Global Alliance for the Treatment of Chagas Disease: Thinking About the Patients

Sylvia GoldSilvia Gold, President, Mundo Sano Foundation
[April 2014]

American Trypanosomiasis, more commonly known as Chagas disease, no longer reflects the geographical scope of the disease. Today, Chagas disease affects people around the world. It is hard to imagine that a disease, discovered over a century ago, which today can be easily diagnosed and for which effective treatment exists, continues to be a problem of severe health impact.

Time for a Reality Check for Neglected Diseases

Bernard Pécoul Bernard Pécoul, Executive Director, DNDi
[February 2014]

The field of neglected disease R&D today is experiencing what could be characterized as a phase of shifting sands: after long inaction for decades, we are now experiencing both remarkable advances and rude set-backs. The innovative ideas, incentives, and R&D partnerships, such as DNDi, that emerged over the last decade are right at the nexus of these movements – of governments, industry, philanthropy, and civil society, among others – and they thus impact directly on our work. They provide a constant reality check that reminds us of just how fragile the field of not-for-profit drug development for neglected diseases is, be it in times of advances or in times of set-backs. We have to take this seriously into account and feed our reflections, debates, and efforts to secure the sustainability of the environment in which we work to solve, in the long term, the problems of millions of patients.